JP2009526756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526756A5 JP2009526756A5 JP2008550490A JP2008550490A JP2009526756A5 JP 2009526756 A5 JP2009526756 A5 JP 2009526756A5 JP 2008550490 A JP2008550490 A JP 2008550490A JP 2008550490 A JP2008550490 A JP 2008550490A JP 2009526756 A5 JP2009526756 A5 JP 2009526756A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- osmrb
- composition
- treating
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003042 antagnostic Effects 0.000 claims 17
- 239000005557 antagonist Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 11
- 101700032890 OSMR Proteins 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 3
- 210000003594 Ganglia, Spinal Anatomy 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 210000000944 Nerve Tissue Anatomy 0.000 claims 1
- 102100019816 OSMR Human genes 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
Claims (11)
- ＩＬ−３１ＲＡアンタゴニストまたはＯＳＭＲｂアンタゴニストを含んでなる、哺乳動物の神経組織の炎症を治療するための組成物。
- ＩＬ−３１ＲａアンタゴニストまたはＯＳＭＲｂアンタゴニストを含んでなる、哺乳動物の疼痛を治療するための組成物。
- ＩＬ−３１ＲａアンタゴニストまたはＯＳＭＲｂアンタゴニストを含んでなる、後根神経節細胞におけるＩＬ−３１によって誘導されるシグナル伝達に拮抗するための組成物。
- ＩＬ−３１ＲａアンタゴニストまたはＯＳＭＲｂアンタゴニストを含んでなる、熱傷に関連した症状を治療するための組成物。
- ＩＬ−３１ＲａアンタゴニストまたはＯＳＭＲｂアンタゴニストを含んでなる、哺乳動物におけるウイルス感染症に関連した症状を治療するための組成物。
- ＩＬ−３１ＲＡアンタゴニストまたはＯＳＭＲｂアンタゴニストを含んでなる、炎症性腸疾患に関連した疼痛を治療するための組成物。
- ＩＬ−３１ＲａアンタゴニストまたはＯＳＭＲＢアンタゴニストが、配列番号２に示すアミノ酸配列の残基２７〜残基１６４を含むポリペプチドに結合する、請求項１〜６のいずれか一項記載の組成物。
- アンタゴニストが、１つまたは複数の可溶性ＩＬ−３１Ｒａサブユニットを含む可溶性受容体である、請求項７記載の組成物。
- アンタゴニストが抗体である、請求項１〜６のいずれか一項記載の組成物。
- 神経組織が、後根神経節または脊髄組織を含む、請求項１〜６のいずれか一項記載の組成物。
- 症状が疼痛またはそう痒である、請求項４又は５記載の組成物。
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75797906P | 2006-01-10 | 2006-01-10 | |
| US75806606P | 2006-01-10 | 2006-01-10 | |
| US77303106P | 2006-02-14 | 2006-02-14 | |
| US80555006P | 2006-06-22 | 2006-06-22 | |
| US80555406P | 2006-06-22 | 2006-06-22 | |
| US80555206P | 2006-06-22 | 2006-06-22 | |
| US82398206P | 2006-08-30 | 2006-08-30 | |
| US82398706P | 2006-08-30 | 2006-08-30 | |
| PCT/US2007/060337 WO2007133816A2 (en) | 2006-01-10 | 2007-01-10 | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526756A JP2009526756A (ja) | 2009-07-23 |
| JP2009526756A5 true JP2009526756A5 (ja) | 2010-02-25 |
Family
ID=38694567
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550490A Pending JP2009526756A (ja) | 2006-01-10 | 2007-01-10 | Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 |
| JP2008550488A Pending JP2009528264A (ja) | 2006-01-10 | 2007-01-10 | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| JP2012240592A Pending JP2013047259A (ja) | 2006-01-10 | 2012-10-31 | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550488A Pending JP2009528264A (ja) | 2006-01-10 | 2007-01-10 | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| JP2012240592A Pending JP2013047259A (ja) | 2006-01-10 | 2012-10-31 | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (22) | US7514077B2 (ja) |
| EP (4) | EP1991581A2 (ja) |
| JP (3) | JP2009526756A (ja) |
| KR (1) | KR101345586B1 (ja) |
| AU (2) | AU2007254715B2 (ja) |
| BR (1) | BRPI0706487A2 (ja) |
| CA (2) | CA2636288C (ja) |
| IL (4) | IL192130A0 (ja) |
| MX (1) | MX2008008831A (ja) |
| RU (1) | RU2565391C2 (ja) |
| WO (2) | WO2007143231A2 (ja) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| ES2254224T3 (es) | 1999-09-27 | 2006-06-16 | Chugai Seiyaku Kabushiki Kaisha | Nueva proteina del receptor de hematopoyetina, nr12. |
| ES2310660T3 (es) * | 2002-01-18 | 2009-01-16 | Zymogenetics, Inc. | Citoquina (ligando zcytor17). |
| JP2008530132A (ja) | 2005-02-14 | 2008-08-07 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
| MX2007009471A (es) | 2005-02-14 | 2008-02-15 | Zymogenetics Inc | Metodos de tratamiento de enfermedades que son mediadas por las celulas positivas al antigeno del linfocito cutaneo. |
| EP2301969B1 (en) | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| AU2007254715B2 (en) | 2005-05-06 | 2013-08-29 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
| JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
| AR061317A1 (es) * | 2006-06-08 | 2008-08-20 | Chugai Pharmaceutical Co Ltd | Agentes para prevenir o tratar enfermedades inflamatorias |
| RU2009111884A (ru) | 2006-09-01 | 2010-10-10 | Займоджинетикс, Инк. (Us) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования |
| JP2010515755A (ja) | 2007-01-10 | 2010-05-13 | ザイモジェネティクス， インコーポレイテッド | 気道過敏および喘息を処置するためのｉｌ−３１の使用法 |
| JP5334319B2 (ja) * | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法 |
| KR102225009B1 (ko) | 2007-09-26 | 2021-03-08 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| BRPI0821110B8 (pt) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo |
| TWI441649B (zh) * | 2007-12-05 | 2014-06-21 | Chugai Pharmaceutical Co Ltd | Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus |
| ES2660036T3 (es) | 2007-12-07 | 2018-03-20 | Zymogenetics, Inc. | Moléculas de anticuerpo humanizadas específicas para IL-31 |
| KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| EP2409990A4 (en) | 2009-03-19 | 2013-01-23 | Chugai Pharmaceutical Co Ltd | VARIANT OF A CONSTANT ANTIBODY REGION |
| EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP2348128A1 (en) * | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8987289B2 (en) * | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US10039792B1 (en) | 2013-03-16 | 2018-08-07 | Brahm Holdings, Llc | Methods for the treatment of inflammation and pain using human birth tissue material composition |
| CN112870368A (zh) * | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
| WO2014194274A2 (en) * | 2013-05-30 | 2014-12-04 | Biogen Idec Ma Inc. | Oncostatin m receptor antigen binding proteins |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| EP3250599B1 (en) * | 2015-01-29 | 2021-04-14 | Oxford University Innovation Limited | Biomarker |
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| BR112017022101A2 (ja) | 2015-04-14 | 2018-07-31 | Chugai Seiyaku Kabushiki Kaisha | An object for prevention and/or a medicine constituent for medical treatment of atopic dermatitis which contain IL-31 antagonist as an active ingredient |
| WO2017033951A1 (ja) * | 2015-08-24 | 2017-03-02 | 学校法人国際医療福祉大学 | 新規鎮痛剤 |
| ES2871036T3 (es) * | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
| EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2 |
| US11319372B2 (en) | 2017-02-21 | 2022-05-03 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) |
| IL301881B1 (en) | 2017-02-23 | 2024-04-01 | Magic Leap Inc | Display system with variable power reflector |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| WO2018190365A1 (ja) * | 2017-04-12 | 2018-10-18 | 国立大学法人九州大学 | 神経障害性疼痛マーカー及びその使用 |
| CN112020511A (zh) | 2018-03-16 | 2020-12-01 | 硕腾服务有限责任公司 | 用于兽医用途的白介素-31单克隆抗体 |
| EP3765069A1 (en) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Peptide vaccines against interleukin-31 |
| KR20210035854A (ko) | 2018-07-23 | 2021-04-01 | 트레비 테라퓨틱스, 인코포레이티드 | 만성 기침, 무호흡증 및 호흡곤란의 치료 |
| RU2707954C1 (ru) * | 2019-01-24 | 2019-12-02 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения онкологической боли |
| AR120512A1 (es) | 2019-11-20 | 2022-02-16 | Chugai Pharmaceutical Co Ltd | Formulaciones que contienen anticuerpos |
| EP4209227A4 (en) * | 2020-09-01 | 2024-05-29 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF PRURITUS IN DIALYSIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE INGREDIENT |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US750795A (en) * | 1904-02-02 | Eugene j | ||
| US4054646A (en) | 1973-07-30 | 1977-10-18 | General Electric | Method and apparatus for detection of antibodies and antigens |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5492841A (en) | 1994-02-18 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Quaternary ammonium immunogenic conjugates and immunoassay reagents |
| US5783672A (en) * | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| US6074849A (en) * | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| RU2175874C2 (ru) * | 1999-03-17 | 2001-11-20 | Борисов Виктор Александрович | Способ лечения нарушений функций центральной нервной системы и устройство для его осуществления |
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2001278852A1 (en) | 2000-06-23 | 2002-01-08 | Genentech Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| CA2412239C (en) | 2000-06-26 | 2013-05-28 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
| AU2001273150A1 (en) | 2000-07-20 | 2002-02-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030059871A1 (en) * | 2000-10-06 | 2003-03-27 | Cosman David J. | Hematopoietin receptors HPR1 and HPR2 |
| WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
| ES2310660T3 (es) | 2002-01-18 | 2009-01-16 | Zymogenetics, Inc. | Citoquina (ligando zcytor17). |
| ES2382800T3 (es) | 2002-01-18 | 2012-06-13 | Zymogenetics, Inc. | Multímeros Zcytor17 receptores de citocinas |
| DK1485477T3 (da) | 2002-02-25 | 2009-08-10 | Genentech Inc | Hidtil ukendt type-1-cytokinreceptor GLM-R |
| JP2008528039A (ja) | 2005-01-28 | 2008-07-31 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１の均質調製物 |
| MX2007009471A (es) | 2005-02-14 | 2008-02-15 | Zymogenetics Inc | Metodos de tratamiento de enfermedades que son mediadas por las celulas positivas al antigeno del linfocito cutaneo. |
| JP2008530132A (ja) * | 2005-02-14 | 2008-08-07 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
| AU2007254715B2 (en) | 2005-05-06 | 2013-08-29 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| EP2301969B1 (en) * | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
| RU2009111884A (ru) | 2006-09-01 | 2010-10-10 | Займоджинетикс, Инк. (Us) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования |
| JP2010515755A (ja) | 2007-01-10 | 2010-05-13 | ザイモジェネティクス， インコーポレイテッド | 気道過敏および喘息を処置するためのｉｌ−３１の使用法 |
| ES2660036T3 (es) | 2007-12-07 | 2018-03-20 | Zymogenetics, Inc. | Moléculas de anticuerpo humanizadas específicas para IL-31 |
-
2007
- 2007-01-10 AU AU2007254715A patent/AU2007254715B2/en active Active
- 2007-01-10 CA CA2636288A patent/CA2636288C/en active Active
- 2007-01-10 EP EP07811781A patent/EP1991581A2/en not_active Withdrawn
- 2007-01-10 WO PCT/US2007/060330 patent/WO2007143231A2/en active Application Filing
- 2007-01-10 MX MX2008008831A patent/MX2008008831A/es active IP Right Grant
- 2007-01-10 RU RU2011137369/15A patent/RU2565391C2/ru active
- 2007-01-10 AU AU2007249713A patent/AU2007249713A1/en not_active Abandoned
- 2007-01-10 JP JP2008550490A patent/JP2009526756A/ja active Pending
- 2007-01-10 US US11/621,829 patent/US7514077B2/en active Active
- 2007-01-10 WO PCT/US2007/060337 patent/WO2007133816A2/en active Application Filing
- 2007-01-10 EP EP14161547.6A patent/EP2749571A3/en not_active Withdrawn
- 2007-01-10 EP EP07777559A patent/EP2001906A2/en not_active Withdrawn
- 2007-01-10 US US11/621,840 patent/US7638126B2/en active Active
- 2007-01-10 EP EP13154292.0A patent/EP2594585A1/en not_active Withdrawn
- 2007-01-10 JP JP2008550488A patent/JP2009528264A/ja active Pending
- 2007-01-10 KR KR1020087019496A patent/KR101345586B1/ko active IP Right Grant
- 2007-01-10 BR BRPI0706487-0A patent/BRPI0706487A2/pt not_active Application Discontinuation
- 2007-01-10 CA CA002633439A patent/CA2633439A1/en not_active Withdrawn
-
2008
- 2008-06-12 IL IL192130A patent/IL192130A0/en unknown
- 2008-06-19 IL IL192296A patent/IL192296A0/en unknown
-
2009
- 2009-02-27 US US12/395,095 patent/US7939068B2/en active Active
- 2009-10-28 US US12/607,831 patent/US7943132B2/en active Active
-
2011
- 2011-03-30 US US13/075,845 patent/US8105591B2/en active Active
- 2011-03-30 US US13/075,412 patent/US8105590B2/en active Active
- 2011-12-20 US US13/331,145 patent/US8377438B2/en active Active
- 2011-12-21 US US13/332,758 patent/US8409571B2/en active Active
-
2012
- 2012-05-09 IL IL219678A patent/IL219678A0/en unknown
- 2012-05-09 IL IL219677A patent/IL219677A0/en unknown
- 2012-10-31 JP JP2012240592A patent/JP2013047259A/ja active Pending
-
2013
- 2013-01-23 US US13/747,899 patent/US8637015B2/en active Active
- 2013-03-07 US US13/788,454 patent/US8685395B2/en active Active
- 2013-12-19 US US14/134,278 patent/US8968732B2/en active Active
-
2014
- 2014-02-07 US US14/175,117 patent/US8974783B2/en active Active
-
2015
- 2015-01-23 US US14/603,406 patent/US9334321B2/en active Active
- 2015-01-27 US US14/606,063 patent/US9334322B2/en active Active
-
2016
- 2016-04-15 US US15/099,639 patent/US9631021B2/en active Active
- 2016-04-15 US US15/099,647 patent/US9631022B2/en active Active
-
2017
- 2017-03-15 US US15/459,901 patent/US9834602B2/en active Active
- 2017-03-16 US US15/461,090 patent/US9828431B2/en active Active
- 2017-10-31 US US15/799,445 patent/US20180044426A1/en not_active Abandoned
- 2017-11-01 US US15/800,980 patent/US20180066050A1/en not_active Abandoned
-
2018
- 2018-12-20 US US16/227,307 patent/US20190112369A1/en not_active Abandoned
- 2018-12-20 US US16/227,266 patent/US20190119372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526756A5 (ja) | ||
| Huang et al. | The new biology of histamine receptors | |
| JP5925178B2 (ja) | α７受容体結合コリン作動性アゴニストを用いる炎症の阻害 | |
| DK1765860T3 (da) | Ny-ESO-T.cellereceptor med höj affinitet | |
| WO2008051306A8 (en) | Soluble tnf receptors and their use in treatment of disease | |
| RU2506274C2 (ru) | Способы скрининга с применением g-белок сопряженных рецепторов и родственных композиций | |
| EA201070091A1 (ru) | Производные пиперидина, пригодные в качестве антагонистов рецептора орексина | |
| JP2012507271A5 (ja) | ||
| EA201100942A1 (ru) | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл | |
| JP2007536932A5 (ja) | ||
| NZ617196A (en) | Activin-actrii antagonists and uses for increasing red blood cell levels | |
| DK2582701T3 (en) | D2 ANTAGONISTS, SYNTHESIS PROCEDURES AND METHODS OF USE | |
| EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| WO2010141249A3 (en) | Generation, characterization and uses thereof of anti-notch3 antibodies | |
| JP2016539096A5 (ja) | ||
| CA2539596A1 (en) | Melanocortin receptor agonists | |
| JP2011528332A5 (ja) | ||
| JP2012517818A5 (ja) | ||
| IN2012DN06588A (ja) | ||
| JP2009506753A5 (ja) | ||
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств | |
| WO2009089062A3 (en) | Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders | |
| NZ599114A (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| WO2010112458A8 (en) | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit | |
| AU2018250210B2 (en) | Stable modulators of gamma-c-cytokine activity |